Physician profile
Michael Choi
NPI 1710471370
$2,351.16
in general payments reported to CMS, 2019-2025
15 companies · $29.86 in 2025
The $29.86 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $319 · 2021: $281 · 2022: $648 · 2023: $68.86 · 2024: $61.74 · 2025: $29.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.62 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $673.78 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $339.99 | 2019-2020 | |
| Allergan, INC. | $282.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $248.88 | 2019-2022 | |
| Alcon Vision LLC | $162.68 | 2022-2024 | Precision 1 |
| Coopervision INC. | $152.71 | 2019-2021 | |
| Biotissue Holdings INC. | $142.95 | 2021 | |
| Bausch & Lomb Americas INC. | $142.18 | 2022-2023 | Miebo |
| Abbvie INC. | $64.54 | 2023-2024 | Vuity, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $39.46 | 2019 | |
| Eyevance Pharmaceuticals LLC | $22.14 | 2019 | |
| Oyster Point Pharma, INC. | $20.51 | 2022 | |
| Visioneering Technologies, INC. | $20.48 | 2021 | |
| Shire North American Group INC | $20.14 | 2019 | |
| Sight Sciences, INC. | $18.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.